Corcid

Quick links to important sections

Corcid

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Corcid

Quick Facts

Property Description
Active Ingredients Aluminium Hydroxide Gel, Magnesium Hydroxide, Omeprazole, Simethicone
Form Oral suspension or chewable tablet
Pharmacological Class Gastrointestinal Agent (Compound Antacid, PPI, Antiflatulent)
Origin/Type Synthetic compounds and inorganic salts

What is Corcid and How is it Classified?

Corcid is a specialized, fixed-dose combination product classified as a multi-action Gastrointestinal Agent. It is fundamentally designed to provide simultaneous, coordinated relief from discomfort and symptoms related to excess stomach acid. The inclusion of Omeprazole establishes its role as a proton pump inhibitor, a class clinically recognized for its efficacy in suppressing gastric acid secretion. This means the medicine is intended not only to neutralize existing acid but also to limit the amount of new acid the stomach produces.

This proprietary formulation stands out because it is a multi-action medication, combining four distinct mechanisms within one preparation. Its unique classification includes components from three major therapeutic groups: compound antacids (Aluminium Hydroxide Gel and Magnesium Hydroxide), a proton pump inhibitor (PPI), and an antiflatulent (Simethicone). This sophisticated, combined approach offers a synchronous action to manage various aspects of gastric distress.


Corcid's Composition and Physical Form

Corcid contains four primary active ingredients: Aluminium Hydroxide Gel, Magnesium Hydroxide, Omeprazole, and Simethicone, and is typically administered via the oral route. The formulation includes inorganic salts and synthetic compounds prepared as a pharmaceutical mixture. Simethicone, which is physically inert and acts as an anti-foaming agent, is confirmed to modify the surface tension of gas bubbles in the gut. This action helps to relieve feelings of pressure and bloating commonly associated with acid discomfort.

Depending on the specific market formulation, Corcid is primarily supplied as an oral suspension or a chewable tablet, facilitating easy and direct administration into the digestive tract. The inclusion of the two inorganic salts provides an immediate chemical buffering capacity, while the Omeprazole component is formulated for systemic absorption and subsequent long-term acid production control.


What is the General Therapeutic Purpose of Corcid?

The general purpose of Corcid is to offer comprehensive relief by integrating rapid acid neutralization with sustained acid production control in the stomach. This multi-pronged strategy addresses both the acute burning sensation caused by existing acid and the underlying mechanisms that lead to its excessive secretion. For instance, Corcid may be generally used to relieve intermittent heartburn and the accompanying bloating. The overall benefit is achieved through the coordinated effort of its active components.

Regulatory References

  1. Omeprazole: MedlinePlus Drug Information
  2. Simethicone - StatPearls - NCBI Bookshelf

What side effects are possible with Corcid?

Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and safety characteristics of Corcid, based on governmental regulatory sources. The profile is defined by frequency classifications, system-organ classes, and specific warnings related to its components.

Frequency-Classified Adverse Reactions

The most common adverse reactions, as classified in regulatory documents, include headache, diarrhea, abdominal pain, nausea, vomiting, and flatulence. Reactions classified as uncommon include sleep disturbance (insomnia), vertigo, dizziness, and skin rash.

Reactions are systematically grouped by System-Organ Class (SOC), affecting systems such as the Gastrointestinal system, Nervous System disorders, Skin and Subcutaneous Tissue disorders, and, rarely, the Blood and Lymphatic System.


Serious Adverse Reactions and Safety Patterns

Serious Adverse Reactions explicitly documented in official labeling, though rare, include anaphylactic shock, severe cutaneous reactions like Stevens-Johnson syndrome, and severe conditions affecting the kidneys or liver, such as acute interstitial nephritis and hepatic failure.

Safety notes tied to the duration of use include the potential for increased risk of bone fracture (hip, wrist, or spine) and hypomagnesemia (low magnesium levels) with prolonged, daily use of the proton pump inhibitor component, generally defined as use exceeding one year.

Population-Specific Constraints

The medicine is contraindicated in individuals with a known hypersensitivity to any of its active components or related PPI class drugs (substituted benzimidazoles). Due to the content of Magnesium Hydroxide and Aluminium Hydroxide, the formulation should be avoided or used with particular caution in patients with severe renal impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

The information regarding Corcid overdose is based strictly on the content documented in official government regulatory documents.


Documented Overdose Manifestations and Risks

Officially documented manifestations reported in association with overdose include headache, dizziness, and constipation. Overdose may also present with more severe signs related to high systemic exposure, primarily affecting the Central Nervous System (CNS). These serious neurological manifestations documented in labeling include confusion, delirium, hallucinations, disorientation, agitation, seizures, and lethargy.

The management approach described in regulatory documents consists of providing symptomatic and supportive treatment, as no specific antidote is detailed in the official labeling.


Population-Specific Overdose Considerations

A heightened risk of severe CNS adverse reactions is documented for certain populations. Elderly patients and individuals with moderate or severe renal impairment are noted to be at increased risk of these neurological effects due to reduced drug clearance. Monitoring for CNS adverse reactions may be required in these specific patient groups following an overdose.


Required Emergency Actions

Immediate medical attention is mandated in the event of any suspected overdose. Official guidance requires individuals to seek immediate medical attention or contact a Poison Control Center right away. Urgent medical help is necessary when any sign of over-ingestion is suspected.

Therapeutic Uses of Corcid

Quick Facts: Corcid (Famotidine)

  • Helps manage duodenal ulcers.
  • Assists in the treatment of gastric ulcers.
  • Provides management for symptoms of gastroesophageal reflux disease (GERD).
  • Used to address pathological hypersecretory conditions.

Corcid (famotidine) is an available option used in the management of conditions associated with excess stomach acid production. It is indicated for prescription use to assist in the healing and maintenance of duodenal and gastric ulcers. This medication is also used to provide management for symptoms associated with gastroesophageal reflux disease (GERD) in adults and children.

Furthermore, Corcid may be used as a treatment option for adults with pathological hypersecretory conditions, which involves the stomach producing high amounts of acid. Over-the-counter formulations of this medicine are available to help prevent and provide relief from occasional heartburn.

Eligibility and Restrictions for Use

Corcid, which contains the proton pump inhibitor (PPI) Omeprazole, is generally prescribed to treat conditions like gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. The decision to use this medication should always be made by a healthcare provider after a complete evaluation of the patient’s medical history.

Contraindications

Corcid should not be used in patients who:

  • Have a known allergy or hypersensitivity to omeprazole or any other PPI (such as lansoprazole, pantoprazole, or esomeprazole).
  • Are concurrently taking medication containing rilpivirine (used to treat HIV infection). Concomitant use with drugs like nelfinavir or atazanavir is also generally avoided.

Precautions and Warnings

Caution and close medical monitoring are required for individuals with certain pre-existing health conditions or circumstances. Inform your doctor if you have:

Condition Recommendation
Liver Problems Use with caution; dose adjustment may be necessary.
Severe Diarrhea May worsen; seek medical advice.
Pregnancy/Breastfeeding Use only if the potential benefit justifies the risk.
History of Fractures Long-term use (over a year) may increase the risk of bone fracture.
Vitamin B12 Deficiency Long-term use (over three years) may decrease B12 absorption.
Symptoms of concern Unexplained weight loss, vomiting blood, difficulty swallowing, or black stools—these require immediate investigation.

It is essential to disclose all medications, supplements, and herbal products being taken to check for potential drug interactions.

What should I know about interactions with other medicines?

Corcid Interactions with other medicines and products

The official interaction profile for Corcid is defined by regulatory restrictions concerning both systemic and physical interactions. Specific drug combinations are formally designated as contraindicated due to high risk or pharmacokinetic conflict. Co-administration with Pimozide, Ergotamine, and Dihydroergotamine is explicitly prohibited in regulatory labeling. Use with the antiplatelet drug Clopidogrel should be avoided due to the documented risk of diminishing its therapeutic antiplatelet effect.

The concurrent use of the antiretrovirals Atazanavir and Nelfinavir is not recommended, as the Omeprazole component significantly reduces their plasma concentrations due to altered gastric pH. The drug can also alter the clearance of substances metabolized through the CYP2C19 enzyme. This metabolic interaction may prolong the elimination of narrow therapeutic index drugs such as Warfarin and Phenytoin, necessitating regulatory monitoring. Furthermore, Corcid may interfere with the absorption of medications whose bioavailability is dependent on gastric acidity, such as Ketoconazole and Iron Salts.

A separate class of interaction involves the antacid components. To minimize the risk of a documented decrease in absorption through physicochemical binding, the administration of the antacid and many other oral medications should be separated by two to three hours. The herbal product St John's Wort should be avoided as it may reduce the drug's plasma levels. In populations with renal impairment, co-administration with Citrates (a food and drink component) is cautioned against due to the documented risk of increased Aluminium accumulation.

Mechanism of Action

Modulating Core Signaling Pathways

Corcid operates by selectively engaging key signaling pathways associated with specific biological signaling patterns. Its mechanism involves acting within domains that rely on receptor- or enzyme-mediated signaling, facilitating the molecular modulation of the target. This targeted action modifies specific intracellular substrates that regulate the downstream activity of cellular processes. Corcid primarily functions as a specific functional modulator of its primary molecular target, altering its conformational state upon binding.


Regulating Mechanistic Cascades and Feedback

The modification of early molecular steps initiates or suppresses signaling sequences—mechanistic cascades—that precede subsequent physiological events. Corcid's activity modulates the signaling magnitude driven by specific mediator activity and influences the intrinsic feedback regulation within the targeted pathways. This sequence promotes a shift toward a more regulated state within the specific molecular networks, resulting in physiological consequences that delineate the drug's activity profile.

Dosage and Administration Information

How Corcid is Used

Corcid's usage is defined by its fixed-dose combination structure, integrating principles for both immediate symptomatic relief and sustained acid control.


Administration Protocol

Field Instruction
Route of administration The medication is limited to the Oral Route.
Dosing schedule The standard dose for short-term use is 10 to 20 mL of the suspension or 2 to 4 chewable tablets per dose.
Timing in relation to meals Dosing is directed to occur between meals and at bedtime to align with periods of anticipated symptomatic need.
Preparation requirements The oral suspension must be shaken well prior to measurement. Chewable tablets are instructed to be chewed thoroughly before being swallowed.
Age-group rules Use in children under 12 years requires specific physician guidance.
Special procedural conditions Caution is instructed for patients with existing renal impairment due to the concentration of antacid components.

Use Constraints

Administration is structured as as-needed (PRN) use with a maximum frequency of up to four times daily (QID). There is an explicit time restriction, stating the maximum daily dosage must not be used for more than 14 consecutive days unless directed by a healthcare professional. This establishes the drug’s role as a temporary, acute intervention and not a long-term maintenance solution.


Summary of Administration Sequence

Instructions mandate that the user first ensure proper preparation—either shaking the suspension or chewing the tablet—before taking the required dose. The dose must be taken between meals or at bedtime. Adherence to the 14-day limit and consideration of the specific caution for renal impairment ensure use aligns with the established procedural protocol.

Recent Clinical Evidence

Corcid: Recent Clinical Evidence

Clinical trials have examined the potential role of Corcid (a proton pump inhibitor) in the management of acid-related disorders. This research aligns with the established use of this class of medication in reducing stomach acid production.

Acute Pain Management

Clinical trials have examined the potential role of this medication in the treatment of acute pain. Studies have evaluated whether patient quality of life changed after one week of dosing. These trials investigated potential timeframes for observed changes in pain sensation. Further research has explored whether this drug is associated with changes in pain sensation. In the studies, the drug was administered with food to assess tolerability.

Chronic Symptom Modulation

Research remains ongoing regarding the long-term use of this medication. Studies have investigated whether chronic symptom changes were maintained over time, which is a key area of focus for sustained management of chronic conditions. The studies did not report on specific guidance regarding driving or operating machinery.

Combination Therapy Trials

Studies have explored the potential benefit of this medication when used in combination with other agents, particularly for severe conditions. Research also examined whether the drug was associated with changes in inflammation markers. The available studies did not directly compare this drug to older treatments for efficacy or safety outcomes.

Key Studies & References

  1. Proton Pump Inhibitors (PPI) - StatPearls (Source for general mechanism and administration)
  2. 25 Years of Proton Pump Inhibitors: A Comprehensive Review

Frequently Asked Questions (FAQ)

Common questions about Corcid (FAQ)


Q: How long does the effect of one dose of Corcid usually last?

Corcid is designed to work in two complementary ways. The antacid components provide immediate neutralization of existing acid upon ingestion. The proton pump inhibitor (PPI) component, which works to suppress new acid production, generally extends for a full day or more because it acts on specific molecular systems in the stomach.


Q: What happens if a person misses taking a dose of Corcid?

Regulatory information for this type of medication indicates that if a dose is missed, it should be administered as soon as possible. If, however, the time is near for the next scheduled dose, the patient should skip the missed dose and take the next dose on time. Regulatory instructions state that two doses must not be administered at once to compensate for a missed dose.


Q: Can Corcid be crushed or split if a person has trouble swallowing pills?

Official instructions specify that chewable tablets must be chewed thoroughly before being swallowed. Since this product contains an acid-suppressing component, regulatory instructions indicate that a decision to alter other forms requires specific professional guidance to avoid compromising the active ingredient and proper function.


Q: Is Corcid safe for use in children or adolescents?

Regulatory documents state that use in children under 12 years requires specific physician guidance. The use and dosage for older children and adolescents must also be determined by a doctor. This requirement is consistent with professional practice for prescription medications in these age groups.


Q: Does Corcid contain any ingredients that commonly cause allergic reactions?

Official information confirms that Corcid is contraindicated in anyone with a known hypersensitivity (severe allergic reaction) to any of its active components or related PPI class drugs. Manufacturers must document every ingredient, including inactive ones (excipients), which are a common cause of hypersensitivity in some people.


Q: What is the typical timeframe before noticing an effect from Corcid?

Corcid has a dual approach to symptom relief. The antacid components provide immediate relief from existing acid symptoms right after ingestion. For the proton pump inhibitor component, official information indicates it may take several days to see the full effect of acid suppression.


Q: What is the recommended advice if a side effect of Corcid is bothersome?

Regulatory information directs patients to report signs or symptoms consistent with adverse reactions to their healthcare provider. The label emphasizes that severe or persistent symptoms, such as severe, watery diarrhea, should be reported promptly to a doctor for proper evaluation.


Q: Are there any specific foods or drinks that should be avoided while on Corcid?

Official labeling cautions against the co-administration of Citrates—substances found in many foods and drinks—in patients with renal impairment (kidney problems). This is a specific precaution due to the documented risk of increased Aluminium accumulation from the antacid component in patients with renal impairment.


Q: Is it described in official sources whether Corcid can be used while breastfeeding?

Official caution states that Corcid should be used during breastfeeding only if the potential benefit justifies the potential risk to the infant. Regulatory data also indicates that limited human data suggests the drug may pass into breastmilk.


Q: Are there age limits or restrictions for taking Corcid?

Official documents address the requirement for specific physician guidance for children under 12 years of age. While no explicit upper age limit is defined in the contraindications, standard regulatory caution applies to elderly patients, especially concerning pre-existing conditions like renal function.


Q: What are the official sources saying about the potential for dependence on Corcid?

Based on the drug's components, chemical classification, and therapeutic action, regulatory data confirms that the drug is not listed as habit-forming or a controlled substance in official drug schedules.


Q: Is Corcid known to cause issues with sleep, such as insomnia or drowsiness?

Official labeling classifies sleep disturbance (insomnia) as an uncommon adverse reaction. Official labeling lists dizziness and vertigo among other uncommon side effects affecting the nervous system.


Q: Does the efficacy of Corcid decrease over time according to research?

Research summaries state that studies have investigated whether chronic symptom changes were maintained over time for this medication. This line of research is a key area of focus for understanding the sustained management of chronic conditions. The summary of studies did not report on the specific findings regarding this research question.


Q: Is Corcid considered a narcotic or controlled substance?

Regulatory data confirms that the drug is not listed as a narcotic or controlled substance in official drug schedules. Its classification as a Gastrointestinal Agent means it is categorized differently from regulated substances.


Q: Is Corcid a medication that requires refrigeration for storage?

The official storage requirements specify that Corcid must be kept at controlled room temperature, typically 20 C to 25 C. Official product documentation states that the medicine does not require refrigeration.


Q: How should unused or expired Corcid be properly disposed of?

Official disposal guidance recommends that unused or expired Corcid should be handled through a drug take-back program or authorized collection site. If those options are unavailable, the official guidance is to follow household trash disposal steps by mixing the medicine with an undesirable substance (like coffee grounds or kitty litter) and sealing it in a container before discarding in the household trash.


Q: Does official information provide any clarification on what to do during a medical emergency while on Corcid?

Regulatory documents list severe, but rare, adverse reactions such as anaphylactic shock and severe cutaneous reactions (like Stevens-Johnson syndrome). The documentation lists these severe conditions as requiring immediate professional medical attention, which is the required response when a severe adverse reaction occurs.

How should Corcid be stored and disposed of?

Corcid (Famotidine) must be stored strictly according to official regulatory requirements to ensure its stability.

Storage Requirements

The medicine requires storage at controlled room temperature, typically 20 C to 25 C. It must be kept in its original container and maintained tightly closed to provide protection from moisture and light. The oral suspension form, if applicable, must be discarded 30 days after initial reconstitution.

It is mandatory to store all forms of Corcid out of the sight and reach of children and pets to prevent accidental ingestion.

Disposal

Unused or expired Corcid should be disposed of immediately via a drug take-back program or an authorized collection site. If these options are unavailable, the official guidance is to follow household trash disposal steps by mixing the medicine with an undesirable substance, then sealing it in a container before discarding. Medicines must not be flushed down the toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Corcid found in:

A-Z Index: